-
Milnacipran
- indication:Milnacipran is used to treat moderate to severe clinical depression and chronic pain.
- pharmacologypharmacology:
- mechanism: Milnacipran inhibits norepinephrine and serotonin reuptake in a 3:1 ratio, in practical use this means a balanced (equal) action upon both transmitters. The serotonin reuptake inhibition is likely to improve depression, while the norepinephrine reuptake inihibition probably improves chronic pain. Milnacipran exerts no significant actions on postynaptic H1, alpha-1, D1, D2, and muscarinic receptors, as well as on benzodiazepine/opiate binding sites. [Wikipedia]
- toxicity:
- absorprion: Milnacipran is well absorbed following oral administration with an absolute bioavailability of 85%. Meals have no effect on absorption.
- halflife: 8 hours
- roouteelimination: It is excreted predominantly unchanged in urine (55%) and has a terminal elimination half-life of about 6 to 8 hours. The main route of elimination of bepotastine besilate is urinary excretion (with approximately 75-90% excreted unchanged in urine).
- volumedistribution: * 400 L
- clearance: